½ÃÀ庸°í¼­
»óǰÄÚµå
1621823

ePrescribing ½ÃÀå : ¿ÀÆÛ¸µ, µô¸®¹ö¸® ¸ðµå, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

ePrescribing Market by Offrings (Services, Solution), Delivery Mode (On premise, Web & Cloud based), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ePrescribing ½ÃÀåÀº 2023³â¿¡ 1¾ï 4,753¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 1¾ï 5,921¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 8.05%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 2¾ï 5,379¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ePrescribing, Áï ÀüÀÚ Ã³¹æÀº ÀÇ·á ó¹æÀüÀ» µðÁöÅзΠÀÛ¼º, Àü¼Û ¹× ÀÛ¼ºÇÏ´Â °ÍÀ» ÀǹÌÇϸç, ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ¿Í ¾à±¹ °£ÀÇ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­ÇÕ´Ï´Ù. ÀÌ ±â¼úÀº ó¹æÀü ¿À·ù¸¦ ÁÙÀ̰í, ȯÀÚ ¾ÈÀüÀ» ³ôÀ̰í, ÀÇ·á È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ ÇʼöÀûÀ̸ç, ePrescribing ½Ã½ºÅÛÀº ÀϹÝÀûÀ¸·Î º´¿ø, Ŭ¸®´Ð, ¾à±¹¿¡¼­ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚ Áß º´¿øÀº 󹿷®ÀÌ ¸¹¾Æ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÁö¸¸, ¼Ò±Ô¸ð Ŭ¸®´Ð°ú ¼Ò¸Å ¾à±¹¿¡¼­µµ äÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ÀÇ·á IT ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Åõ¾à ¿À·ù °¨¼Ò¿¡ ´ëÇÑ °ü½É Áõ°¡, Á¤ºÎÀÇ ÀüÀÚó¹æÀü µµÀÔ ÃËÁø Á¤Ã¥ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á·ÎÀÇ Àüȯ°ú »óÈ£¿î¿ë¼º Ç¥ÁØÀÇ È®´ë´Â ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷°ú ±âÁ¸ ¾÷üµéÀÌ ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡ ¸Â°Ô ¼Ö·ç¼ÇÀ» Çõ½ÅÇÏ°í ¸ÂÃãÈ­ÇÒ ¼ö ÀÖ´Â ±æÀ» ¿­¾îÁÖ¸ç ÁÖ¸ñÇÒ ¸¸ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ±â¾÷Àº °³ÀÎÈ­µÈ ¾à¹° °ü¸®¸¦ À§ÇÑ AI ÅëÇÕ, »çÀ̹ö º¸¾È ±â´É °­È­, »ç¿ë ÆíÀǼº Çâ»óÀ» À§ÇÑ »ç¿ëÀÚ ÀÎÅÍÆäÀ̽º °³¼± µîÀ» ¸ð»öÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ ½ÃÀåÀº ±âÁ¸ ÀüÀڰǰ­±â·Ï(EHR) ½Ã½ºÅÛ°úÀÇ ÅëÇÕ, ³ôÀº Ãʱâ ÅõÀÚ ºñ¿ë, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹× º¸¾È¿¡ ´ëÇÑ ¿ì·Á¿Í °°Àº ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Å±â¼ú ½Àµæ¿¡ ´ëÇÑ ÀϺΠÀÇ·á Àü¹®°¡µéÀÇ °ÅºÎ°¨µµ ÇѰè Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ Áö¿ª¸¶´Ù ±ÔÁ¦°¡ ´Ù¸£±â ¶§¹®¿¡ ½ÃÀå È®´ë Àü·«ÀÌ º¹ÀâÇØÁú ¼ö ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ßÀº ¼Ò±Ô¸ð Ŭ¸®´ÐÀ» À§ÇÑ ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» °³¹ßÇϰí, µ¥ÀÌÅÍ °øÀ¯ ´É·ÂÀ» Çâ»ó½Ã۸ç, ÁøÈ­ÇÏ´Â ±ÔÁ¦ Ç¥ÁØÀ» ÁؼöÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾î¾ß ÇÕ´Ï´Ù. ¾ÈÀüÇÑ °Å·¡¸¦ À§ÇÑ ºí·ÏüÀΰú ¿¹Ãø ºÐ¼®À» À§ÇÑ ¸Ó½Å·¯´×¿¡ ´ëÇÑ ¿¬±¸´Â ½ÃÀåÀÇ ÁøÈ­¸¦ ´õ¿í ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ½ÃÀåÀº ¿ªµ¿ÀûÀ̸ç, ¿ÏÀüÇÑ µðÁöÅÐ Çコ ÅëÇÕÀ» ÇâÇÑ Á¡ÁøÀûÀÎ Ãß¼¼°¡ Ư¡À̸ç, ÇöÀçÀÇ Á¦¾àÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÏ°í »õ·Î¿î ±â¼úÀ» Ȱ¿ëÇÒ ¼ö ÀÖ´Â ±â¾÷¿¡°Ô Å« ¼ºÀå ÀáÀç·ÂÀ» Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023³â] 1¾ï 4,753¸¸ ´Þ·¯
¿¹Ãø³â[2024³â] 1¾ï 5,921¸¸ ´Þ·¯
¿¹Ãø³â[2030³â] 2¾ï 5,379¸¸ ´Þ·¯
CAGR(%) 8.05%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ePrescribing ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³

ePrescribing ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ÀüÀÚ ¹èÇÕ ½Ã½ºÅÛ »ç¿ëÀ» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎÀÇ ±¸»ó°ú ±ÔÁ¦
    • ÀüÀÚÀǹ«±â·Ï(EHR) µµÀÔ È®´ë
    • ÀÇ·áÀÇ Áú°ú ȯÀÚ ¾ÈÀü Çâ»ó¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Ãʱ⠼³Á¤ ¹× À¯Áöº¸¼ö ºñ¿ëÀÌ ³ô½À´Ï´Ù.
  • ½ÃÀå ±âȸ
    • ½ÅÈï Áö¿ª »ç¾÷ È®ÀåÀ» À§ÇÑ ÅõÀÚ Áõ°¡, ÀÇ»ç°áÁ¤ Áö¿ø ½Ã½ºÅÛ ¹ßÀü
    • ¿ø°ÝÀÇ·á¿ÍÀÇ ÅëÇÕ, ¸ÂÃãÇü ÀǷḦ À§ÇÑ ºÐ¼® Ȱ¿ë
  • ½ÃÀå °úÁ¦
    • µ¥ÀÌÅÍÀÇ ÇÁ¶óÀ̹ö½Ã ¹× º¸¾È¿¡ ´ëÇÑ ¿ì·Á

Porter's Five Forces: ePrescribing ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« Åø

"Portre's Five Forces:" ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇϱâ À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» º¸¿ÏÇϸç ÀáÀçÀû µµÀüÀ» ÇÇÇÔÀ¸·Î½á º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ePrescribing ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

PESTLE ºÐ¼®

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ePrescribing ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ´ã°í ÀÖÀ¸¸ç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ePrescribing ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

ePrescribing ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ¼¼ºÐÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º: ePrescribing ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ePrescribing ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ: ePrescribing ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

ePrescribing ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
      • ÀüÀÚ ¹èÇÕ ½Ã½ºÅÛÀÇ »ç¿ëÀ» ÃËÁøÇÏ´Â Á¤ºÎ ±¸»ó°ú ±ÔÁ¦
      • ÀüÀڰǰ­±â·Ï(EHR)ÀÇ µµÀÔ Áõ°¡
      • ÀÇ·á Áú°ú ȯÀÚ ¾ÈÀü¼ºÀÇ Çâ»ó¿¡ ´ëÇÑ »õ·Î¿î ¼ö¿ä
    • ¾ïÁ¦¿äÀÎ
      • Ãʱ⼳Á¤°ú Á¤ºñÀÇ °íºñ¿ë
    • ±âȸ
      • ½Å±Ô Áö¿ª¿¡ ´ëÇÑ ÅõÀÚ È®´ë¿Í ÀÇ»ç°áÁ¤ Áö¿ø½Ã½ºÅÛÀÇ Áøº¸
      • ¿ø°ÝÀÇ·á¿ÍÀÇ ÅëÇÕ, ¸ÂÃãÇü ÀǷḦ À§ÇÑ ºÐ¼®ÀÇ È°¿ë
    • °úÁ¦
      • µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿Í º¸¾È¿¡ °üÇÑ ¿ì·Á
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • ÄÄÆ÷³ÍÆ® : º¸´Ù ±¤¹üÀ§ÇÑ ÀÇ·á IT ½Ã½ºÅÛ¿ë ÅëÇÕ ¼Ö·ç¼ÇÀÇ ÀûÇÕ¼º
    • µµÀÔ : ½Ç½Ã°£ µ¥ÀÌÅÍ °øÀ¯¿Í ¾÷µ¥ÀÌÆ®¿¡ ÀÇÇØ Ŭ¶ó¿ìµå»ó¿¡¼­ÀÇ µµÀÔÀÌ ÁøÇàµÈ´Ù.
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ePrescribing ½ÃÀå Á¦°ø¿ø : ¿ÀÆÛ¸µº°

  • ¼­·Ð
  • ¼­ºñ½º
    • ½ÇÀå
    • ³×Æ®¿öÅ©
  • ¼Ö·ç¼Ç
    • ÅëÇÕ
    • ½ºÅĵå¾ó·Ð

Á¦7Àå ePrescribing ½ÃÀå : µô¸®¹ö¸® ¸ðµåº°

  • ¼­·Ð
  • ¿ÂÇÁ·¹¹Ì½º
  • À¥°ú Ŭ¶ó¿ìµå ±â¹Ý

Á¦8Àå ePrescribing ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼­·Ð
  • º´¿ø
  • ¾à±¹
  • ÀÇ»ç ¿ÀÇǽº

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ePrescribing ½ÃÀå

  • ¼­·Ð
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ePrescribing ½ÃÀå

  • ¼­·Ð
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ePrescribing ½ÃÀå

  • ¼­·Ð
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Rhyl, ȯÀÚ¿ë »õ·Î¿î ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛÀ» µµÀÔ
    • DrFirst Healthcare Innovations°¡ MEDITECH¿Í Á¦ÈÞÇÏ¿© ij³ª´Ù¿¡¼­ ÀüÀÚ ¹èÇÕÀ» ÃßÁø
    • BoomerangFX°¡ DrFirst¿Í Á¦ÈÞÇÏ¿© ºÏ¹Ì Àü¿ªÀÇ ¸ÞµðÄà ¿¡½ºÅׯ½ Ŭ¸®´Ð¿ë ÀüÀÚ ¹èÇÕÀ» °³½Ã
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • 75health
  • Allscripts Healthcare Solutions Inc.
  • athenahealth, Inc.
  • Dosespot by PRN Software, LLC
  • DrChrono
  • DrFirst Inc.
  • eazyScripts Technology, LLC
  • eClinicalWorks
  • eMDs, Inc. by CompuGroup Medical
  • Epocrates Inc.
  • Healthie Inc.
  • iCoreConnect
  • Intelligent Medical Software
  • Kareo, Inc. by Tebra Technologies, Inc.
  • MDToolbox
  • MedicalMine Inc.
  • Networking Technology, Inc.
  • NextGen Healthcare, Inc.
  • Optum, Inc.
  • Oracle Corporation
  • Pabau
  • Provet Cloud
  • Qualifacts Systems, LLC
  • Surescripts, LLC
  • Wolters Kluwer N.V.
KSA 25.01.16

The ePrescribing Market was valued at USD 147.53 million in 2023, expected to reach USD 159.21 million in 2024, and is projected to grow at a CAGR of 8.05%, to USD 253.79 million by 2030.

ePrescribing, or electronic prescribing, refers to the digital creation, transmission, and filling of medical prescriptions, streamlining the process between healthcare providers and pharmacies. This technology is essential for reducing prescription errors, enhancing patient safety, and improving healthcare efficiency. ePrescribing systems are typically applied in hospitals, clinics, and pharmacies. Among end users, hospitals hold significant market share due to high prescription volume, but adoption is expanding across smaller practices and retail pharmacies. Key growth factors in the market include rising demand for healthcare IT solutions, increased focus on reducing medication errors, and government initiatives promoting the adoption of ePrescribing. The ongoing shift towards telemedicine and expanding interoperability standards present notable opportunities, providing avenues for new entrants and established players to innovate and tailor solutions for varied healthcare settings. To capitalize on these opportunities, companies can explore integrating AI for personalized medication management, enhancing cybersecurity features, and improving user interfaces for better usability. However, the market faces challenges such as integration with existing electronic health record (EHR) systems, high initial investments, and concerns regarding data privacy and security. Limitations also include resistance from some healthcare professionals due to the learning curve associated with new technology. Furthermore, regulatory variations across different regions can complicate market expansion strategies. Innovation and research should focus on developing cost-effective solutions aimed at smaller practices, improving data-sharing capabilities, and ensuring compliance with evolving regulatory standards. Research into blockchain for secure transactions and machine learning for predictive analytics could further drive market evolution. Overall, the market is dynamic, characterized by a progressive trend towards full digital health integration, offering substantial growth potential for those who can effectively manage current limitations and leverage emerging technologies.

KEY MARKET STATISTICS
Base Year [2023] USD 147.53 million
Estimated Year [2024] USD 159.21 million
Forecast Year [2030] USD 253.79 million
CAGR (%) 8.05%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving ePrescribing Market

The ePrescribing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Government initiatives and regulations promoting the use of e-prescribing systems
    • Increasing adoption of electronic health records (EHRs)
    • Emerging demand for improved healthcare quality and patient safety
  • Market Restraints
    • High initial setup and maintenance costs
  • Market Opportunities
    • Rising investments to expand in emerging regions, and advancements in decision support systems
    • Integration with telemedicine, leveraging analytics for personalized medicine
  • Market Challenges
    • Concerns about data privacy and security

Porter's Five Forces: A Strategic Tool for Navigating the ePrescribing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the ePrescribing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the ePrescribing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the ePrescribing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the ePrescribing Market

A detailed market share analysis in the ePrescribing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the ePrescribing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the ePrescribing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the ePrescribing Market

A strategic analysis of the ePrescribing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the ePrescribing Market, highlighting leading vendors and their innovative profiles. These include 75health, Allscripts Healthcare Solutions Inc., athenahealth, Inc., Dosespot by PRN Software, LLC, DrChrono, DrFirst Inc., eazyScripts Technology, LLC, eClinicalWorks, eMDs, Inc. by CompuGroup Medical, Epocrates Inc., Healthie Inc., iCoreConnect, Intelligent Medical Software, Kareo, Inc. by Tebra Technologies, Inc., MDToolbox, MedicalMine Inc., Networking Technology, Inc., NextGen Healthcare, Inc., Optum, Inc., Oracle Corporation, Pabau, Provet Cloud, Qualifacts Systems, LLC, Surescripts, LLC, and Wolters Kluwer N.V..

Market Segmentation & Coverage

This research report categorizes the ePrescribing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offrings, market is studied across Services and Solution. The Services is further studied across Implementation and Network. The Solution is further studied across Integrated, and Standalone.
  • Based on Delivery Mode, market is studied across On premise and Web & Cloud based.
  • Based on End User, market is studied across Hospitals, Pharmacies, and Physician Offices.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Government initiatives and regulations promoting the use of e-prescribing systems
      • 5.1.1.2. Increasing adoption of electronic health records (EHRs)
      • 5.1.1.3. Emerging demand for improved healthcare quality and patient safety
    • 5.1.2. Restraints
      • 5.1.2.1. High initial setup and maintenance costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising investments to expand in emerging regions, and advancements in decision support systems
      • 5.1.3.2. Integration with telemedicine, leveraging analytics for personalized medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns about data privacy and security
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: Suitability of integrated solutions for broader healthcare IT system
    • 5.2.2. Deployment: Inclination towards on-cloud deployment owing to real time data sharing and updates
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. ePrescribing Market, by Offrings

  • 6.1. Introduction
  • 6.2. Services
    • 6.2.1. Implementation
    • 6.2.2. Network
  • 6.3. Solution
    • 6.3.1. Integrated,
    • 6.3.2. Standalone

7. ePrescribing Market, by Delivery Mode

  • 7.1. Introduction
  • 7.2. On premise
  • 7.3. Web & Cloud based

8. ePrescribing Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Pharmacies
  • 8.4. Physician Offices

9. Americas ePrescribing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific ePrescribing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa ePrescribing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Rhyl to Launch New Electronic Prescription System for Patients
    • 12.3.2. DrFirst Healthcare Innovations Collaborates with MEDITECH to Power E-Prescribing in Canada
    • 12.3.3. BoomerangFX Partners with DrFirst to Launch E-Prescribing for Aesthetic Medicine Practices Across North America
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 75health
  • 2. Allscripts Healthcare Solutions Inc.
  • 3. athenahealth, Inc.
  • 4. Dosespot by PRN Software, LLC
  • 5. DrChrono
  • 6. DrFirst Inc.
  • 7. eazyScripts Technology, LLC
  • 8. eClinicalWorks
  • 9. eMDs, Inc. by CompuGroup Medical
  • 10. Epocrates Inc.
  • 11. Healthie Inc.
  • 12. iCoreConnect
  • 13. Intelligent Medical Software
  • 14. Kareo, Inc. by Tebra Technologies, Inc.
  • 15. MDToolbox
  • 16. MedicalMine Inc.
  • 17. Networking Technology, Inc.
  • 18. NextGen Healthcare, Inc.
  • 19. Optum, Inc.
  • 20. Oracle Corporation
  • 21. Pabau
  • 22. Provet Cloud
  • 23. Qualifacts Systems, LLC
  • 24. Surescripts, LLC
  • 25. Wolters Kluwer N.V.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦